



RESEARCH GRANT PROGRAM

The ACPMP Research Foundation is dedicated to funding promising research for the diagnosis, treatment, and cure of Appendix Cancer and Pseudomyxoma Peritonei (PMP). The ACPMP Research Grant Program is currently administered by the highly respected National Organization for Rare Disorders (NORD).

ACPMP has distributed \$1,200,000 in the form of 25 research grants over the past 10 years, with another \$100,000 to be issued at the end of 2019; visit acpmp.org/research.

Grant recipients are selected by the independent NORD Medical Advisory Committee. Information and the application form for the ACPMP Research Grants available through NORD are available on our website at acpmp.org on our Research page, or the NORD website, rarediseases.org, on their Request for Proposals page.

Questions or requests for application forms may be directed to NORD at: (800)999-NORD or research@rarediseases.org.

The 2019 grant cycle timeline is generally as follows:

- Letter of Intent Deadline is June 18, 2019.
- Full proposal invitations will be announced in August, 2019.
- Full proposals must be received by NORD in October, 2019.
- Award announcements will be made in December, 2019.

ACPMP/NORD RESEARCH OBJECTIVES:

The purpose of the ACPMP/NORD Research Grant Program is to encourage meritorious clinical studies designed to improve the diagnosis or therapy of Appendix Cancer and/or Pseudomyxoma Peritonei. For this RFP, studies related to PMP and appendix cancer as a disease of origin for PMP will be considered. Grants will be awarded to qualified researchers to initiate small scientific studies and/or clinical research studies, the results of which could be used to obtain funding from NIH, FDA or other funding agencies, or to attract a corporate sponsor. Procedures or proposed approaches may be new, based on recent biochemical, molecular genetic, or pharmacological evidence, or in preliminary stages of clinical investigation. Evaluation of proposals will include careful consideration of protocol design, objectiveness of parameters measured, and statistical evaluation proposed. Protocols that will focus on early detection, diagnosis, etiology, or treatment (pharmacological, devices, surgery, or dietary) or cure will be given priority.

ACPMP Research Foundation Research Grant Program Recipients, 2009-2018

GRANTS AWARDED - 2018

"Immune system enhanced appendiceal cancer organoids for ex vivo determination of immunotherapy efficacy in appendiceal cancer"

Konstantinos Votanopoulos, MD, PhD; Wake Forest University, Winston-Salem, NC, USA
\$50,000/2-year

"Modulation of Tumor Immune Microenvironment for Enhanced Therapy of Pseudomyxoma Peritonei"

Shyh-Dar Li, PhD; University of British Columbia, Vancouver, BC Canada
\$50,000/2-year

GRANTS AWARDED - 2017

"Exploiting Systems Vulnerabilities in the Appendix Cancer and Pseudomyxoma Peritonei Oncogenome"

J. Silvio Gutkind, PhD, Moores Cancer Center (UCSD – San Diego, CA)
\$50,000/2-year

"Role of bacteria in the development and progression of pseudomyxoma peritonei"

D. Scott Merrell, PhD, Uniformed Services University of the Health Sciences (Bethesda, MD)
\$50,000/2-year

"PATrol 4 Cure (Pseudomyxoma Angiogenesis Translational Research Testing 4 anti-angiogenic drugs with animal models for PMP to propose a cure)"

Marc Pocard, MD, PhD; Professor of Surgery, Director of Research, National Institute of Health and Medical Research, Hopital Lariboisiere & Director, Angiogenesis and Translational Research Unit, Paris, France
\$50,000/2 year

"Novel animal models for the study of PMP etiology and treatment"

Traci L. Testerman, PhD, University of South Carolina School of Medicine (Columbia, SC)
\$50,000/2-year

GRANTS AWARDED - 2016

"The effect of Bromelain and N-acetylcysteine on appendiceal adenocarcinoma and pseudomyxoma peritonei in vitro and LS174T in vivo: development of a novel mucolytic agent and progression to a phase I/II study"

David L. Morris, MD, PhD, St George Hospital, Australia; \$50,000/2-year

GRANTS AWARDED - 2015

"Developing a Novel Drug Delivery Platform for Targeting Hyaluronan"

Dr. Wilbur Bowne, Associate Professor in the Department of Surgery, Drexel University College of Medicine and Dr. Hao Cheng, Assistant Professor, Materials Science and Engineering, Drexel University, Philadelphia, PA, USA; \$50,000/2-year

"Cure4PMP — Genomic Biomarkers and Actionable Targets"

Kjersti Flatmark, MD, PhD, Radium Hospital, Oslo University Hospital Norway; \$50,000/2-year

GRANTS AWARDED - 2014

"Targeted Parallel Pathway Blockade as a Treatment Option for Pseudomyxoma Peritonei"

Venkatesh Govindarajan, PhD Department of Surgery, Creighton University, Omaha, NE, USA; \$50,000/2-year

"T cell Immunotherapy for Pseudomyxoma Peritonei"

Steven Katz, MD, Roger Williams Medical Center, USA and Cherif Boutros MD, University of Maryland School of Medicine, USA; \$50,000/2-year

GRANTS AWARDED - 2013

"Targeting Core Signaling Networks in Mucinous Adenocarcinoma of the Appendix"

Andrew Lowy, MD, FACS, Moores Cancer Center, University of California, San Diego, USA; \$50,000/2-year

GRANTS AWARDED - 2013 (CTD)

"Carcinoembryonic Antigen – A Pro-Angiogenic Factor in Pseudomyxoma Peritonei – is a Potential Target for Therapy"

Peter Thomas, PhD Surgery and Biomedical Sciences, Creighton University, Omaha, NE, USA; \$25,000/2-year

"PMP: Biologic Foundations for New Treatment Options"

Venkatesh Govindarajan, PhD Department of Surgery, Creighton University, Omaha, NE, USA; \$25,000/2-year

GRANTS AWARDED - 2012

"Genomic Analysis of Pseudomyxoma Peritonei and Cancer of the Appendix"

Edward Levine, MD, Wake Forest School of Medicine, North Carolina, USA; \$50,000/2 year

"Significance of a Novel Genetic Alteration in Pseudomyxoma Peritonei"

Shigeki Sekine, MD, PhD, National Cancer Center Research Institute, Tokyo, Japan; \$50,000/2 year

GRANTS AWARDED - 2011

"Pseudomyxoma Peritonei: Prognostic Analysis of Micro-RNA and Other Biological Factors Using Tissue Microarray"

Marcello Deraco, MD, Fondazione IRCCS Istituto Nazionale Tumori (National Cancer Institute), Milano, Italy; \$50,000/2 year

"Sequencing the Cancer Genome of Mucinous Adenocarcinoma of the Appendix"

Andrew Lowy, MD, FACS, Moores Cancer Center, University of California, San Diego, CA, USA; \$50,000/2 year

"Preclinical Targeting of the Goblet Cell Differentiation Pathway in Pseudomyxoma Peritonei"

Andrew Renehan, MD, PhD, FRCS, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK; \$50,000/2 year

GRANTS AWARDED - 2010

"Treating PMP Using Small Molecule Inhibitors of Gel-forming Mucin Productions"

Zongsheng Guo, PhD, Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA, USA; \$50,000/2 year

"MicroRNA Profiling of Clinically Different Pseudomyxoma Peritonei Phenotypes"

Brendan Moran, MD, FRCS and Alex Mirnezami, PhD, FRCS, National Pseudomyxoma Peritonei Center-Basingstoke and North Hampshire Hospital NHS Foundation Trust, Basingstoke, UK --and-- The Cancer Research UK Center, Southampton General Hospital, Southampton, UK; \$50,000/2 year

"Translational Biology of Pseudomyxoma Peritonei"

Aaron A. Mansfield, MD, Robert Miller, MD, MS, Julian Molina, MD, PhD, Fernando Quevado, MD, Department of Radiation Oncology and Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA; \$50,000/2 year

GRANTS AWARDED - 2009

"Identification of molecular targets in pseudomyxoma peritonei via clonal analyses of metastases"

Herbert Zeh, MD, PhD, University of Pittsburgh, Pittsburgh, PA, USA; \$50,000/2 year

"Establishing Methods for Evaluating Anti-tumor Therapies for Treatment of Pseudomyxoma Peritonei Using Gene Profiles and Immortalized Cells"

Andrew Renehan, MD, PhD, FRCS, The Christie NHS Foundation Trust, University of Manchester, Manchester, UK; \$50,000/2 year

"Development of Animal Models for the Study of Pseudomyxoma and Evaluation of the Role of Anti-Angiogenesis in the Control of this Tumor"

Marc Pocard, MD, PhD, National Institute of Health and Medical Research, Hopital Lariboisiere & Director, Angiogenesis and Translational Research Unit, Paris, France; \$50,000/2 year